Cancer therapy targets rigid tissue

Nature ◽  
2017 ◽  
Vol 548 (7665) ◽  
pp. 9-9
2010 ◽  
Vol 10 (6) ◽  
pp. 935-954 ◽  
Author(s):  
Brahma N Singh ◽  
Guanghua Zhang ◽  
Yi L Hwa ◽  
Jinping Li ◽  
Sean C Dowdy ◽  
...  

2016 ◽  
Vol 1 (3) ◽  
Author(s):  
Teresa L. Wargasetia

MicroRNAs (miRNAs) are involved in the signaling circuits regulation within a cell andtheir deregulation plays an important role in cancer development and progression. In thisreview, we discussed miRNA biogenesis, miRNA function and the effect of miRNA abnormalitiesin cellular pathways that led to transformation of normal cells into cancer cells, as well as theindication of miRNAs as diagnostic and prognostic biomarkers of various types of cancer, asbiomarkers to predict the response to cancer therapy and the potential for development ofmiRNAs as cancer targeted therapy.Keywords: miRNA, cancer, diagnostic biomarker, prognostic biomarker, cancer therapy


Biomedicines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 107
Author(s):  
Yousef Risha ◽  
Vanessa Susevski ◽  
Nico Hüttmann ◽  
Suttinee Poolsup ◽  
Zoran Minic ◽  
...  

Membrane-derived extracellular vesicles, referred to as microvesicles (MVs), have been proposed to participate in several cancer diseases. In this study, MV fractions were isolated by differential ultracentrifugation from a metastatic breast cancer (BC) cell line MDA-MB-231 and a non-cancerous breast cell line MCF10A, then analyzed by nano-liquid chromatography coupled to tandem mass spectrometry. A total of 1519 MV proteins were identified from both cell lines. The data obtained were compared to previously analyzed proteins from small extracellular vesicles (sEVs), revealing 1272 proteins present in both MVs and sEVs derived from the MDA-MB-231 cell line. Among the 89 proteins unique to MDA-MB-231 MVs, three enzymes: ornithine aminotransferase (OAT), transaldolase (TALDO1) and bleomycin hydrolase (BLMH) were previously proposed as cancer therapy targets. These proteins were enzymatically validated in cells, sEVs, and MVs derived from both cell lines. The specific activity of OAT and TALDO1 was significantly higher in MDA-MB-231-derived MVs than in MCF10A MVs. BLMH was highly expressed in MDA-MB-231-derived MVs, compared to MCF10A MVs. This study shows that MVs carry functional metabolic enzymes and provides a framework for future studies of their biological role in BC and potential in therapeutic applications.


2011 ◽  
Vol 89 (4) ◽  
pp. 359-376 ◽  
Author(s):  
Marta Gladych ◽  
Aneta Wojtyla ◽  
Blazej Rubis

Since telomerase has been recognized as a relevant factor distinguishing cancer cells from normal cells, it has become a very promising target for anti-cancer therapy. A correlation between short telomere length and increased mortality was revealed in many studies. The telomerase expression/activity appears to be one of the most crucial factors to study to improve cancer therapy and prevention. However, this multisubunit enzymatic complex can be regulated at various levels. Thus, several strategies have been proposed to control telomerase in cancer cells such as anti-sense technology against TR and TERT, ribozymes against TERT, anti-estrogens, progesterone, vitamin D, retinoic acid, quadruplex stabilizers, telomere and telomerase targeting agents, modulation of interaction with other proteins involved in the regulation of telomerase and telomeres, etc. However, the transcription control of key telomerase subunits seems to play the crucial role in whole complexes activity and cancer cells immortality. Thus, the research of telomerase regulation can bring significant insight into the knowledge concerning stem cells metabolism but also ageing. This review summarizes the current state of knowledge of numerous telomerase regulation mechanisms at the transcription level in human that might become attractive anti-cancer therapy targets.


2021 ◽  
Author(s):  
Jintong Liu ◽  
Jing Huang ◽  
Lei Zhang ◽  
Jianping Lei

We review the general principle of the design and functional modulation of nanoscaled MOF heterostructures, and biomedical applications in enhanced therapy.


2007 ◽  
Vol 37 (14) ◽  
pp. 23
Author(s):  
KERRI WACHTER
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document